Harmandeep Ltd. is a private company in the pharmaceutical industry. It has been preparing its financial statements in accordance with ASPE. Since it has plans to go public in the next three to five years, it is considering changing to IFRS for the current year. It wishes to adopt policies that will maximize the return on shareholders equity. Based on the draft financial statements prepared in accordance with ASPE, its net income for Year 5 is $417,000, and its shareholders equity at December 31, Year 5 is $3,670,000.

Harmandeep has engaged you to reconcile net income and shareholders equity from ASPE to IFRS. You have identified the following five areas in which IFRS differs from ASPE:

1. Impaired loansoriginal versus market rate of interest
2. Interest costscapitalize versus expense
3. Actuarial gains/lossesrecognize immediately in net income versus recognize immediately in other comprehensive income
4. Compound financial instrumentdebt versus equity components
5. Income taxesfuture income tax method or taxes payable method

Harmandeep provides the following information with respect to each of these accounting differences.

Impaired Loans

One of Harmandeeps debtors is in financial difficulty and defaulted on its loan payment during the year. The outstanding balance on this loan receivable at the end of Year 5 was $277,000. Harmandeep agreed to accept five annual payments of $67,000 with the first payment due at December 31, Year 6, as a full settlement of the loan. The original interest rate on the loan was 10%. The market rate of interest for this type of loan is 8%. No adjustment has been made for the impairment of the loan receivable.

Interest Costs

Harmandeep arranged a loan of $1,140,000 to finance the construction of a warehouse: $570,000 was borrowed on March 1, Year 5, and another $570,000 was borrowed on October 1, Year 5. The loan is repayable over five years with an interest rate of 8%, with the first payment due on September 30, Year 6. The warehouse was nearly complete at the end of Year 5. No interest has been accrued on the loan at the end of Year 5.

Actuarial Gains/Losses

Harmandeep instituted a defined benefit pension plan in Year 3. The first actuarial evaluation, which was done as at June 30, Year 5, indicated an actuarial gain of $175,500. The expected average remaining service life of the employee workforce was 15 years at the time of the actuarial evaluation. The actuarial gain has not yet been recognized in the preliminary financial statements.

Compound Financial Instrument

Harmandeep issued bonds for proceeds of $1,340,000 on December 31, Year 5. The bonds are convertible into common shares at any time within the next five years. The bonds would have been worth only for $1,256,000 if they did not have the conversion feature. The proceeds on the bonds have been recognized as long-term debt in the preliminary financial statements.

Income Tax

Harmandeeps income tax rate has been and is expected to continue at 40%. Assume that any adjustments to accounting income for the above items are fully deductible or taxable for tax purposes. The preliminary financial statements reflect the tax payable method of accounting for income taxes. If the future income tax method were adopted, future tax liabilities should be set up for $317,000 at the end of Year 4 and $374,000 at the end of Year 5.

Required:

Prepare a schedule to convert net income and total shareholders equity from the preliminary financial statements amounts to amounts under ASPE and IFRS. Where accounting choices exist, choose policies that minimize return on total shareholders equity under ASPE and maximize return on total shareholders equity under IFRS. (Leave no cells blank - be certain to enter "0" wherever required. Do not round Present value factor for an ordinary annuity. Round intermediate computations and final answers to nearest whole dollar value. Negative amounts should be indicated by a minus sign. Omit $ signs in your response.)

Description Preliminary financial statements Loan impairment Accrued interest payable Actuarial gains Equity portion of compound instrument Future tax liability Revised values